Results 141 to 150 of about 40,250 (264)

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +5 more
wiley   +1 more source

Diketopyrrolopyrrole-based two-dimensional poly(arylene vinylene)s with high charge carrier mobility. [PDF]

Nat Commun
Zhao R, Yu H, Zhang H, Gao L, Khan AH, Liu C, Li X, Chu X, Fu Y, Pohl D, Wrzesińska-Lashkova A, Brunner E, Vaynzof Y, Wang HI, Bonn M, Heine T, Wang M, Feng X.   +17 more
europepmc   +1 more source

Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D).
Rakesh Sahay, Ambanna Gowda, Manish Kumar Singh, A. Gopal Rao, Ramesh Duraisamy, Dinesh Gangwani, Jitendra Shukla, Vikas Agarwal, Sandesh Sahebarao Patil, Ambrish C., Satish Babu K. N., Arvind Palawat, Sandip Krishnrao Gofne, Abhay Kumar Sahoo, Pradeep Kumar Rai, Raisa Shaikh, Shruti Saha, Dipak Patil, Pravin Ghadge, Piyush Patel, Lalit Lakhwani, Suyog Mehta, Sadhna Joglekar   +22 more
wiley   +1 more source

HDAC3 Preserves the primordial follicle reserve by epigenetically suppressing ferroptosis in pregranulosa cells. [PDF]

Cell Mol Life Sci
Chen Z, Guo J, Gao M, Wang H, Cai H, Yang Q, Yang X, Lin Y, Zhu Z, Qin S, Bao Y, Zhao T, Liu L, Wang T, Zhou B, Zhang H, Wang J, Guo H, Xia G, Wang C.   +19 more
europepmc   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Bee pollen-derived peptide with dual DPP-IV Inhibition and glucose transport modulation. [PDF]

Sci Rep
Mongkolnkrajang U, Kuptawach K, Sangtanoo P, Saisavoey T, Boonserm P, Reamtong O, Srimongkol P, Karnchanatat A.   +7 more
europepmc   +1 more source

Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed‐Dose Titration of Weekly Insulin Efsitora in Insulin‐Naïve Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the QWINT‐1 phase 3 Trial, once‐weekly insulin efsitora alfa (efsitora) administered using an innovative fixed‐dose regimen demonstrated noninferior HbA1c reduction versus once‐daily insulin glargine U100 (glargine) over 52 weeks in insulin‐naïve adults with type 2 diabetes.
Lisa Connery, Julio Rosenstock, Neda Rasouli, Alice Y. Y. Cheng, Andreas Liebl, Qianqian Wang, Vitoria Pires, Alastair Knights, Michael B. Davidson, Christopher J. Child   +9 more
wiley   +1 more source

Service user experiences of a nationally implemented diabetes prevention programme in England: a qualitative interview study. [PDF]

Health Psychol Behav Med
Higgs P, Hawkes RE, Miles LM, Dack C, French DP.   +4 more
europepmc   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source

Stacked ensemble learning and in-silico profiling reveal dual DPP-IV and SGLT2 inhibitors from Moringa oleifera metabolites. [PDF]

Sci Rep
Letuku MK, Mohlala MG, Appiah-Kubi P, Singh A, Nuapia YB.   +4 more
europepmc   +1 more source